Kamada Shuts Down Phase 3 Study For Genetic Condition, Reiterates Outlook

Kamada Ltd. (NASDAQ: KMDA) on Monday said it will discontinue its Phase 3 InnovAATe trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency (AATD).

Benzinga • Dec 8, 2025

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Kamada Ltd. (KMDA) Discusses Discontinuation of Phase 3 Inhaled AAT Clinical Trial and Financial Outlook Transcript

Seeking Alpha • Dec 8, 2025

Kamada (KMDA) is an Incredible Growth Stock: 3 Reasons Why

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Nov 11, 2025

Kamada Ltd. (KMDA) Q3 2025 Earnings Call Transcript

Kamada Ltd. ( KMDA ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Brian Ritchie - Lifesci Advisors, LLC Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Sidoti - Sidoti & Company, LLC Presentation Operator Good morning.

Seeking Alpha • Nov 10, 2025

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and nine months ended September 30, 2025.

GlobeNewsWire • Nov 10, 2025

Kamada (KMDA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Nov 10, 2025

Kamada (KMDA) Misses Q3 Earnings Estimates

Kamada (KMDA) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Nov 10, 2025

Countdown to Kamada (KMDA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Kamada (KMDA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Zacks Investment Research • Nov 6, 2025

Should Value Investors Buy Kamada (KMDA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Nov 5, 2025

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.

GlobeNewsWire • Nov 3, 2025